Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-HoFH: LIB003 vs Evolocumab in Homozygous Familial Hypercholesterolemia
NCT04034485Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 3 trial of lerodalcibep in familial hypercholesterolemia (FH), sponsored by LIB Therapeutics. Started Dec 2019; status: completed.
02
Drugs
lerodalcibep
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT04034485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034485.